BMC infectious diseases · 2021
Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Umemura Machiko, Suda Goki, Tsukamoto Shihori, Ebata Ko, Takahash Shinjiro, Sasaki Takashi, Nakajima Sae, Hirata Koji, Ozasa Mariko, Takano Masatoshi, Katagiri Masaki, Sakamoto Naoya
Аннотация
BACKGROUND: In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies.
CASE PRESENTATION: We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion.
CONCLUSION: On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.
CASE PRESENTATION: We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion.
CONCLUSION: On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.
Предметные рубрики MeSH
Aminoisobutyric AcidsAntineoplastic Combined Chemotherapy ProtocolsAntiviral AgentsBenzimidazolesCyclophosphamideCyclopropanesDoxorubicinGenotypeHepacivirusHepatitis CHumansLactams, MacrocyclicLeucineLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneProlinePyrrolidinesQuinoxalinesRNA, ViralRituximabSulfonamidesSustained Virologic ResponseVincristineViral Load